300 related articles for article (PubMed ID: 30355737)
21. Differential sensitivity of various human tumors to inhibition of polyamine biosynthesis in vivo.
Saydjari R; Alexander RW; Upp JR; Barranco SC; Townsend CM; Thompson JC
Int J Cancer; 1991 Jan; 47(1):44-8. PubMed ID: 1985877
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effect of vitamin K1 on growth and polyamine biosynthesis of human gastric and colon carcinoma cell lines.
Linsalata M; Orlando A; Tutino V; Notarnicola M; D'Attoma B; Russo F
Int J Oncol; 2015 Aug; 47(2):773-81. PubMed ID: 26043965
[TBL] [Abstract][Full Text] [Related]
24. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
25. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
[TBL] [Abstract][Full Text] [Related]
26. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet.
Reddy BS; Nayini J; Tokumo K; Rigotty J; Zang E; Kelloff G
Cancer Res; 1990 May; 50(9):2562-8. PubMed ID: 2109653
[TBL] [Abstract][Full Text] [Related]
27. Polyamines and cancer: implications for chemotherapy and chemoprevention.
Nowotarski SL; Woster PM; Casero RA
Expert Rev Mol Med; 2013 Feb; 15():e3. PubMed ID: 23432971
[TBL] [Abstract][Full Text] [Related]
28. The gastrointestinal polyamine source depletion enhances DFMO induced polyamine depletion in MCF-7 human breast cancer cells in vivo.
Levêque J; Burtin F; Catros-Quemener V; Havouis R; Moulinoux JP
Anticancer Res; 1998; 18(4A):2663-8. PubMed ID: 9703925
[TBL] [Abstract][Full Text] [Related]
29. Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice.
Yerushalmi HF; Besselsen DG; Ignatenko NA; Blohm-Mangone KA; Padilla-Torres JL; Stringer DE; Guillen JM; Holubec H; Payne CM; Gerner EW
Mol Carcinog; 2006 Oct; 45(10):764-73. PubMed ID: 16705737
[TBL] [Abstract][Full Text] [Related]
30. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Reddy BS
Environ Mol Mutagen; 2004; 44(1):26-35. PubMed ID: 15199544
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial prevention of carcinogenic risk in a model for familial colon cancer.
Telang N; Katdare M
Oncol Rep; 2007 Apr; 17(4):909-14. PubMed ID: 17342335
[TBL] [Abstract][Full Text] [Related]
32. Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy.
Harari PM; Fuller DJ; Carper SW; Croghan MK; Meyskens FL; Shimm DS; Gerner EW
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):89-96. PubMed ID: 2116388
[TBL] [Abstract][Full Text] [Related]
33. Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO.
Weeks RS; Vanderwerf SM; Carlson CL; Burns MR; O'Day CL; Cai F; Devens BH; Webb HK
Exp Cell Res; 2000 Nov; 261(1):293-302. PubMed ID: 11082299
[TBL] [Abstract][Full Text] [Related]
34. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Mackenzie GG; Sun Y; Huang L; Xie G; Ouyang N; Gupta RC; Johnson F; Komninou D; Kopelovich L; Rigas B
Gastroenterology; 2010 Oct; 139(4):1320-32. PubMed ID: 20600034
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporine and alpha-difluoromethylornithine exhibit differential effects on colon and pancreatic cancer in vitro.
Saydjari R; Townsend CM; Barranco SC; Thompson JC
Invest New Drugs; 1987; 5(3):251-8. PubMed ID: 3117720
[TBL] [Abstract][Full Text] [Related]
36. TRPC1 and ORAI1 channels in colon cancer.
Villalobos C; Hernández-Morales M; Gutiérrez LG; Núñez L
Cell Calcium; 2019 Jul; 81():59-66. PubMed ID: 31203007
[TBL] [Abstract][Full Text] [Related]
37. Individual and combined effects of alpha-difluoromethylornithine and ovariectomy on the growth and polyamine milieu of experimental breast cancer in rats.
Manni A; Badger B; Glikman P; Bartholomew M; Santner S; Demers L
Cancer Res; 1989 Jul; 49(13):3529-34. PubMed ID: 2499419
[TBL] [Abstract][Full Text] [Related]
38. Polyamines and Cancer.
Damiani E; Wallace HM
Methods Mol Biol; 2018; 1694():469-488. PubMed ID: 29080189
[TBL] [Abstract][Full Text] [Related]
39. Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer.
Janakiram NB; Mohammed A; Bryant T; Zhang Y; Brewer M; Duff A; Biddick L; Singh A; Lightfoot S; Steele VE; Rao CV
Sci Rep; 2016 Nov; 6():37046. PubMed ID: 27841323
[TBL] [Abstract][Full Text] [Related]
40. Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer.
Meyskens FL; Gerner EW
J Cell Biochem Suppl; 1995; 22():126-31. PubMed ID: 8538189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
